Investigational Treatment Combining TG1050, an HBV-Specific Immunotherapeutic, with Direct Acting Antivirals or Immunomodulators, Improves Sustained Antiviral Effects and Immune Responses in HBV-Persistent Mice
HEPATOLOGY（2018）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined